NVIDIA's Meta Llama 3 large language model, powered by accelerated computing, is revolutionizing healthcare and life sciences workflows.

Llama 3 is available as a downloadable NVIDIA NIM inference microservice, aiding developers in creating innovative applications across various healthcare sectors.

In digital biology, Llama 3 enhances drug discovery and clinical trials, improving research efficiency and prediction accuracy.

AI solutions like Deloitte's Atlas AI and Transcripta Bio's Conductor AI leverage Llama 3 for intelligent drug discovery and transcriptome analysis.

NVIDIA NIM supports clinical trials with companies like Quantiphi and ConcertAI developing generative AI solutions to improve patient outcomes and streamline research processes.

Mendel AI uses Llama 3 for clinical data analysis and cohort selection, showing significant performance improvement.

In digital surgery, Activ Surgical integrates Llama 3 for real-time surgical guidance, aiming to reduce complication rates and enhance patient safety.

Digital health companies like SimBioSys, Artisight, AITEM, and Abridge implement Llama 3 for personalized patient care, automation of clinical processes, and physician-patient interaction improvements.

The NVIDIA Inception program supports startups like Transcripta Bio, Activ Surgical, SimBioSys, Artisight, AITEM, and Abridge in leveraging cutting-edge technology for healthcare innovations.

The NVIDIA NIM collection, available with NVIDIA AI Enterprise, streamlines the development and deployment of AI applications in various industries.

Overall, the adoption of Llama 3 NIM is reshaping healthcare by enabling advanced AI solutions that enhance patient care, streamline research processes, and improve healthcare efficiency.

Join NVIDIA at COMPUTEX to learn more about the transformative impact of generative AI in healthcare and other industries.